The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | The role of the microenvironment in T-cell lymphoma and the promise of pembrolizumab in this disease
Swaminathan Iyer, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the important role of the microenvironment in T-cell lymphoma disease progression and the importance of agents targeting PD-1, such as pembrolizumab. Dr Iyer also highlights some results from a study evaluating the use of pembrolizumab in combination with romidepsin for the treatment of T-cell lymphoma, and the promise of this combination approach. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
CRISPR, SEAGEN, MERCK, RHIZEN, ACROTECH, LEGEND, INNATE
